Quest Diagnostics (DGX) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Quest Diagnostics · Health Care · ref. ETF XLV · 51 calls · price $244.61
What the company does: Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.
📈 Quest Diagnostics (DGX) stock price
$244.61+36.5% over range
Aug 28, 25low $173.49 · high $245Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
29% recommend buying · 7 analysts
📊 JPI status : Quest Diagnostics has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 DGX price target & analyst consensus — price $245
The price target · all analysts combined (7 targets)
Highest target · 1 firm of 7$260+6.3%
Median target · of 7 targets$250+2.2%
Lowest target · 1 firm of 7$210-14.1%
Current price$244.61
Where these 7 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
571%
$250 ↔ $260
Below
229%
$210 ↔ $232
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: JP Morgan — 67% of its targets hit on this sector (355 calls tested). It aims for $250 (+2.2 %), call made on July 29, 2026, maturing on July 29, 2027 (30 d ago).
The 6 reliable analysts
$250+2.2 %
The 1 other firm
$210-14 %
How to read it: the 6 reliable firms are not filtered by optimism — 5 aim above the price, 1 below, hence their $250 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 7 ratings (last 6 months)
Strong Buy00%
Buy229%
Hold571%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 DGX price target all
All 51 calls, one by one, with our verdict on each firm.
→ See all 51 targets, analyst by analyst💡 The best analysts on DGX most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in DGX? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Quest Diagnostics? The JPI assistant answers using our backtest data.
💰 Quest Diagnostics dividend: yield, history & growth › open the full page
1.51%annual yield
📈 Steady dividend — 14 yrs of consecutive dividend increases
That's ~$3.26 per share per year.
📈 Quest Diagnostics fundamentals: valuation, margins & growth › open the full page
P/E 26.0Net margin 9.2 %Revenue growth +10.2 %Fairly valued
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 10 %
2023
Rev −6%Profit −10%
2024
Rev +7%Profit +2%
2025
Rev +12%Profit +14%
🔎 Detailed analyses
✅ Historical analyst reliability on DGX
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Baird ↗ | 100% | +17.3% | 4 |
| Citigroup ↗ | 100% | +14.8% | 4 |
| Deutsche Bank ↗ | 100% | +8.0% | 3 |
| UBS ↗ | 100% | +5.3% | 2 |
| Mizuho ↗ | 79% | +12.8% | 14 |
| Jefferies ↗ | 67% | +16.0% | 3 |
| Credit Suisse | 67% | +6.5% | 6 |
| Barclays ↗ | 67% | +6.3% | 3 |
| Morgan Stanley ↗ | 58% | +5.7% | 12 |
| Canaccord Genuity ↗ | 57% | +4.6% | 7 |
See the other 5 firms
| Wells Fargo ↗ | 25% | -25.3% | 4 |
| Goldman Sachs ↗ | 33% | -5.8% | 3 |
| Keybanc ↗ | 33% | -4.7% | 3 |
| Argus Research ↗ | 33% | -2.2% | 3 |
| B of A Securities ↗ | 56% | +1.1% | 9 |
📊 What $1,000 invested in Quest Diagnostics would be worth › open the full page
In short — $1,000 invested in Quest Diagnostics 10 years ago would be worth $2,979 today, i.e. +12%/yr on average. Best year: 2021 (+45%), worst: 2018 (-15%). Price performance, excluding dividends.
If I'd invested $1,000 in Quest Diagnostics
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,405 | +40% |
| 3 years ago | $1,355 | +35% |
| 5 years ago | $1,779 | +78% |
Return by year (Quest Diagnostics)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +22% | $1,221 (+22%) |
| 2025 | +15% | $1,405 (+40%) |
| 2024 | +9% | $1,537 (+54%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Quest Diagnostics
Loading news…
📋 All analyst calls on DGX
Filtered on — · ✕ show all
■ Neutral neutral · not a buy · 🎯$250
Price at call : $235.22 — gap to target +6%
Today : $244.61 — gap to target +2%
🎯 on DGX : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Jul 28, 27
matures : Jul 28, 27
■ Neutral neutral · not a buy · 🎯$232
Price at call : $231.84 — gap to target +0%
Today : $244.61 — gap to target -5%
🎯 on DGX : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jul 25, 27
matures : Jul 25, 27
▲ Outperform · 🎯$260
Price at call : $231.84 — upside +12%
Today : $244.61 — upside +6%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
Truist Securities ↗
Jul 24, 26
■ Hold neutral · not a buy · 🎯$250
Price at call : $231.84 — gap to target +8%
Today : $244.61 — gap to target +2%
🎯 on DGX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
▲ Overweight · 🎯$250
Price at call : $231.84 — upside +8%
Today : $244.61 — upside +2%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
■ Neutral neutral · not a buy · 🎯$255
Price at call : $227.86 — gap to target +12%
Today : $244.61 — gap to target +4%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
■ Neutral neutral · not a buy · 🎯$236
Price at call : $207.35 — gap to target +14%
Today : $244.61 — gap to target -4%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
■ Neutral neutral · not a buy · 🎯$220
Price at call : $199.53 — gap to target +10%
Today : $244.61 — gap to target -10%
🎯 on DGX : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Apr 22, 27
matures : Apr 22, 27
See the other 43 calls, newest to oldest
■ Neutral neutral · not a buy · 🎯$229
Price at call : $204 — gap to target +12%
Today : $244.61 — gap to target -6%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Apr 22, 27
matures : Apr 22, 27
▲ Overweight · 🎯$230
Price at call : $204 — upside +13%
Today : $244.61 — upside -6%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Apr 22, 27
matures : Apr 22, 27
Truist Securities ↗
Apr 22, 26
■ Hold neutral · not a buy · 🎯$225
Price at call : $204 — gap to target +10%
Today : $244.61 — gap to target -8%
🎯 on DGX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Apr 22, 27
matures : Apr 22, 27
Evercore ISI Group ↗
Apr 8, 26
■ In-Line neutral · not a buy · 🎯$210
Price at call : $197.82 — gap to target +6%
Today : $244.61 — gap to target -14%
🎯 on DGX : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Apr 8, 27
matures : Apr 8, 27
▲ Outperform · 🎯$235
Price at call : $206.86 — upside +14%
Today : $244.61 — upside -4%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Feb 12, 27
matures : Feb 12, 27
Truist Securities ↗
Feb 11, 26
■ Hold neutral · not a buy · 🎯$220
Price at call : $206.86 — gap to target +6%
Today : $244.61 — gap to target -10%
🎯 on DGX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
■ Neutral neutral · not a buy · 🎯$210
Price at call : $206.86 — gap to target +2%
Today : $244.61 — gap to target -14%
🎯 on DGX : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
Evercore ISI Group ↗
Feb 11, 26
■ In-Line neutral · not a buy · 🎯$220
Price at call : $209.32 — gap to target +5%
Today : $244.61 — gap to target -10%
🎯 on DGX : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
▲ Overweight · 🎯$225
Price at call : $209.32 — upside +7%
Today : $244.61 — upside -8%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
▲ Buy · 🎯$220
Price at call : $209.32 — upside +5%
Today : $244.61 — upside -10%
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Feb 11, 27
matures : Feb 11, 27
■ Neutral neutral · not a buy · 🎯$215
Price at call : $209.32 — gap to target +3%
Today : $244.61 — gap to target -12%
🎯 on DGX : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Feb 10, 27
matures : Feb 10, 27
Piper Sandler ↗
Oct 27, 25
■ Neutral neutral · not a buy · 🎯$200
Price at call : $178.28 — gap to target +12%
Today : $244.61 — gap to target -18%
🎯 on DGX : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Oct 27, 26
matures : Oct 27, 26
■ Equal-Weight neutral · not a buy · 🎯$195
Price at call : $183.23 — gap to target +6%
Today : $244.61 — gap to target -20%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Oct 22, 26
matures : Oct 22, 26
Truist Securities ↗
Oct 22, 25
■ Hold neutral · not a buy · 🎯$205
Price at call : $183.23 — gap to target +12%
Today : $244.61 — gap to target -16%
🎯 on DGX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Oct 22, 26
matures : Oct 22, 26
Leerink Partners ↗
Oct 21, 25
▲ Outperform · 🎯$210
Price at call : $181.17 — upside +16%
Today : $244.61 — upside -14%
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Oct 21, 26
matures : Oct 21, 26
▲ Buy · 🎯$215
Price at call : $181.17 — upside +19%
Today : $244.61 — upside -12%
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Oct 21, 26
matures : Oct 21, 26
■ Neutral neutral · not a buy · 🎯$190
Price at call : $190.41 — gap to target -0%
Today : $244.61 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Oct 17, 26
matures : Oct 17, 26
▲ Outperform · 🎯$210
Price at call : $189.51 — upside +11%
Today : $244.61 — upside -14%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Oct 17, 26
matures : Oct 17, 26
Evercore ISI Group ↗
Oct 8, 25
■ In-Line neutral · not a buy · 🎯$190
Price at call : $180.89 — gap to target +5%
Today : $244.61 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Oct 8, 26
matures : Oct 8, 26
■ Equal-Weight neutral · not a buy · 🎯$190
Price at call : $179.33 — gap to target +6%
Today : $244.61 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Oct 2, 26
matures : Oct 2, 26
■ Neutral neutral · not a buy · 🎯$194
Price at call : $180.36 — gap to target +8%
Today : $244.61 — gap to target -21%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Aug 25, 26
matures : Aug 25, 26
■ Neutral neutral · not a buy · 🎯$180
Price at call : $171.9 — gap to target +5%
Today : $244.61 — gap to target -26%
🎯 on DGX : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jul 23, 26
matures : Jul 23, 26
Truist Securities ↗
Jul 23, 25
■ Hold neutral · not a buy · 🎯$192
Price at call : $171.9 — gap to target +12%
Today : $244.61 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 23, 26
matures : Jul 23, 26
Deutsche Bank ↗
Jul 23, 25
■ Hold neutral · not a buy · 🎯$178
Price at call : $171.9 — gap to target +4%
Today : $244.61 — gap to target -27%
🎯 on DGX : no call matured yet · 📊 on Health : 53.3% · +4.5% (291 calls)
in progress (365j)
matures : Jul 23, 26
matures : Jul 23, 26
▲ Buy · 🎯$200
Price at call : $170.48 — upside +17%
Today : $244.61 — upside -18%
Expected +17% · Actual +34% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 50.8% · +4.5% (380 calls)
+33.7%
stock +34% · XLV +18%
matured Jul 22, 26
■ Neutral neutral · not a buy · 🎯$175
Price at call : $166.45 — gap to target +5%
Today : $244.61 — gap to target -28%
🎯 on DGX : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jul 18, 26
matures : Jul 18, 26
■ Neutral neutral · not a buy · 🎯$190
Price at call : $176.11 — gap to target +8%
Today : $244.61 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : May 6, 26
matures : May 6, 26
Piper Sandler ↗
Apr 28, 25
■ Neutral neutral · not a buy · 🎯$200
Price at call : $178.5 — gap to target +12%
Today : $244.61 — gap to target -18%
🎯 on DGX : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Apr 28, 26
matures : Apr 28, 26
Truist Securities ↗
Apr 23, 25
■ Hold neutral · not a buy · 🎯$190
Price at call : $175.87 — gap to target +8%
Today : $244.61 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Apr 23, 26
matures : Apr 23, 26
■ Equal-Weight neutral · not a buy · 🎯$185
Price at call : $173.57 — gap to target +7%
Today : $244.61 — gap to target -24%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Apr 23, 26
matures : Apr 23, 26
Evercore ISI Group ↗
Apr 23, 25
■ In-Line neutral · not a buy · 🎯$180
Price at call : $173.57 — gap to target +4%
Today : $244.61 — gap to target -26%
🎯 on DGX : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Apr 23, 26
matures : Apr 23, 26
▲ Outperform · 🎯$194
Price at call : $173.57 — upside +12%
Today : $244.61 — upside -21%
Expected +12% · Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
+15.0%
stock +15% · XLV +8%
matured Apr 23, 26
▲ Outperform · 🎯$189
Price at call : $164.06 — upside +15%
Today : $244.61 — upside -23%
Expected +15% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 52.1% · +3.5% (217 calls)
+20.6%
stock +21% · XLV +8%
matured Apr 9, 26
Redburn Atlantic
Apr 2, 25
▲ Buy · 🎯$195
Price at call : $167.96 — upside +16%
Today : $244.61 — upside -20%
Expected +16% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 unranked overall
+17.9%
stock +18% · XLV +2%
matured Apr 2, 26
▲ Outperform · 🎯$191
Price at call : $167.11 — upside +14%
Today : $244.61 — upside -22%
Expected +14% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
+17.1%
stock +17% · XLV -1%
matured Mar 20, 26
■ Neutral neutral · not a buy · 🎯$185
Price at call : $175.01 — gap to target +6%
Today : $244.61 — gap to target -24%
🎯 on DGX : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Mar 4, 26
matures : Mar 4, 26
■ Neutral neutral · not a buy · 🎯$180
Price at call : $164.87 — gap to target +9%
Today : $244.61 — gap to target -26%
🎯 on DGX : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Feb 4, 26
matures : Feb 4, 26
▲ Outperform · 🎯$178
Price at call : $163.36 — upside +9%
Today : $244.61 — upside -27%
Expected +9% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 52.1% · +3.5% (217 calls)
+15.8%
stock +16% · XLV +6%
matured Feb 3, 26
■ Neutral neutral · not a buy · 🎯$170
Price at call : $163.36 — gap to target +4%
Today : $244.61 — gap to target -31%
🎯 on DGX : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Feb 3, 26
matures : Feb 3, 26
Piper Sandler ↗
Feb 3, 25
■ Neutral neutral · not a buy · 🎯$180
Price at call : $163.36 — gap to target +10%
Today : $244.61 — gap to target -26%
🎯 on DGX : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Feb 3, 26
matures : Feb 3, 26
Truist Securities ↗
Jan 31, 25
■ Hold neutral · not a buy · 🎯$182
Price at call : $162.47 — gap to target +12%
Today : $244.61 — gap to target -26%
🎯 on DGX : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jan 31, 26
matures : Jan 31, 26
■ Equal-Weight neutral · not a buy · 🎯$175
Price at call : $163.1 — gap to target +7%
Today : $244.61 — gap to target -28%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Jan 31, 26
matures : Jan 31, 26
Leerink Partners ↗
Jan 6, 25
▲ Outperform · 🎯$174
Price at call : $152.27 — upside +14%
Today : $244.61 — upside -29%
Expected +14% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
+18.5%
stock +19% · XLV +14%
matured Jan 6, 26
Frequently asked questions
Should I buy Quest Diagnostics stock?
This isn't buy advice. For Quest Diagnostics, the analyst consensus is "Hold", with an average price target of $250 (+2% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (4 calls tracked on Quest Diagnostics). We show the numbers — you decide.
Is it too late to buy Quest Diagnostics? How high can it go?
The most bullish analyst target on Quest Diagnostics is $260 (+6% above today's price); the average is $250. That's the upside they see. Check how reliable those analysts have actually been on Quest Diagnostics on our site before trusting it.
Is Quest Diagnostics still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 15 analysts have a real record on Quest Diagnostics, the best hitting 100% over 4 calls. Current consensus: "Hold". Make your call on data, not noise.
Should you invest in Quest Diagnostics? The case for and against
The arguments for and against, one by one, from the numbers: why invest in DGX (and why hesitate).
What has Quest Diagnostics's past performance been?
Historical returns and a "how much if I had invested" calculator: DGX performance & returns.
Does Quest Diagnostics pay a dividend?
Yield, consistency and growth history of the dividend: DGX's dividend.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX